Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IB Clinical Trial on Adjuvant Low-dose Ipilimumab Plus Nivolumab Following the Resection of Melanoma Macrometastases

Next Previous
X
Search
Trial Profile

A Phase IB Clinical Trial on Adjuvant Low-dose Ipilimumab Plus Nivolumab Following the Resection of Melanoma Macrometastases

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 12 Jan 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
  • Indications Malignant melanoma
  • Focus Adverse reactions

    • Most Recent Events

    • 21 Sep 2020 Results assessing C-reactive protein as biomarker for immune-related adverse events in melanoma patients treated with immune checkpoint inhibitors in the adjuvant setting using pooled data from (NCT02941744, and an observational study) presented at the 45th European Society for Medical Oncology Congress
    • 04 Jun 2019 According to results presented at the 55th Annual Meeting of the American Society of Clinical Oncology, secondary endpoints for this trial included safety, distant metastasis-free survival (DMFS) and overall survival (OS).
    • 04 Jun 2019 According to results presented at the 55th Annual Meeting of the American Society of Clinical Oncology, recruitment to Cohort-B was closed prematurely following registration of nivolumab in the adjuvant setting by EMA.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top